Patents by Inventor Michael McFarlane
Michael McFarlane has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9097588Abstract: A UV radiation (UVR) response indicator comprises a first UVB and/or UVA radiation sensitive material which has been modified so as to display an altered characteristic in a delayed manner in response to UVB and/or UVA radiation exposure. The UV indicator is capable of displaying exposure to increased UV radiation over a period of time. The present invention also relates to a method of displaying a relative amount of exposure to UVR by a UV indicator over a period of time. The invention is particularly useful in detecting the level of exposure to sunlight or sunbed radiation.Type: GrantFiled: December 18, 2009Date of Patent: August 4, 2015Assignee: Intellego Technologies ABInventors: Andrew Mills, Michael McFarlane, Kate McDiarmid, Pauline Grosshans
-
Patent number: 8754240Abstract: The present invention relates to a chemical process for the manufacture of a compound of Formula IIType: GrantFiled: November 17, 2010Date of Patent: June 17, 2014Assignee: AstraZeneca ABInventors: Euan Alexander Arnott, John Crosby, Mathew Charles Evans, James Gair Ford, Martin Francis Jones, Kevin William Leslie, Ian Michael McFarlane, George Joseph Sependa
-
Publication number: 20130053729Abstract: Embodiments relate generally to urine diversion devices for positioning, in use, at least partly within a toilet bowl. The device in some embodiments comprises a body defining a basin and having a collection side and diverting means to divert urine received in the basin toward the collection side; foldable wings coupled to opposed sides of the body and positionable to overlie at least part of respective opposed sides of a toilet seat; and a cradle to hold a urine receptacle and extending from the collection side of the body, the cradle arranged to support the urine receptacle to receive urine diverted toward the collection side.Type: ApplicationFiled: May 11, 2011Publication date: February 28, 2013Applicant: FWEE PTY LTDInventors: Darinka Stevic-Wages, Brendan McKeegan, Phillip Michael McFarlane, Paul Charlwood, Luca Abate
-
Publication number: 20120137958Abstract: A UV radiation (UVR) response indicator comprises a first UVB and/or UVA radiation sensitive material which has been modified so as to display an altered characteristic in a delayed manner in response to UVB and/or UVA radiation exposure. The UV indicator is capable of displaying exposure to increased UV radiation over a period of time. The present invention also relates to a method of displaying a relative amount of exposure to UVR by a UV indicator over a period of time. The invention is particularly useful in detecting the level of exposure to sunlight or sunbed radiation.Type: ApplicationFiled: December 18, 2009Publication date: June 7, 2012Inventors: Andrew Mills, Michael McFarlane, Kate McDiarmid, Pauline Grosshans
-
Publication number: 20110253722Abstract: A method for waterproofing a mobile device and a waterproofed mobile device are provided. The method is designed to keep the internal components from elements, such as water, the can damage the mobile device. The method adds a protective coating of a lightweight sealable, heat shrinkable plastic to the internal components of the mobile device and heat shrinks the ends of the of the a lightweight sealable, heat shrinkable plastic together to waterproof the internal components.Type: ApplicationFiled: April 20, 2010Publication date: October 20, 2011Applicant: TOMORROW'S INNOVATIONSInventors: Cleveland Morrow, Michael McFarlane
-
Publication number: 20110257395Abstract: The present invention relates to chemical processes for the manufacture of certain quinazoline derivatives, or pharmaceutically acceptable salts thereof. The invention also relates to processes for the manufacture of certain intermediates useful in the manufacture of the quinazoline derivatives and to processes for the manufacture of the quinazoline derivatives utilising said intermediates. In particular, the present invention relates to chemical processes and intermediates useful in the manufacture of the compound 4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline.Type: ApplicationFiled: November 17, 2010Publication date: October 20, 2011Applicant: AstraZeneca ABInventors: Euan Alexander Arnott, John Crosby, Matthew Charles Evans, James Gair Ford, Martin Francis Jones, Kevin William Leslie, Ian Michael McFarlane, George Joseph Sependa
-
Patent number: 7851623Abstract: The present invention relates to chemical processes for the manufacture of certain quinazoline derivatives, or pharmaceutically acceptable salts thereof. The invention also relates to processes for the manufacture of certain intermediates useful in the manufacture of the quinazoline derivatives and to processes for the manufacture of the quinazoline derivatives utilising said intermediates. In particular, the present invention relates to chemical processes and intermediates useful in the manufacture of the compound 4-[(4-fluoro-2-methy-1-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline starting from a compound of Formula IX: wherein R4 is a protecting group; or an intermediate there between, using process steps, reagents and conditions as described.Type: GrantFiled: October 31, 2007Date of Patent: December 14, 2010Assignee: AstraZeneca ABInventors: Euan Alexander Arnott, John Crosby, Matthew Charles Evans, James Gair Ford, Martin Francis Jones, Kevin William Leslie, Ian Michael McFarlane, George Joseph Sependa
-
Publication number: 20080221322Abstract: The present invention relates to chemical processes for the manufacture of certain quinazoline derivatives, or pharmaceutically acceptable salts thereof. The invention also relates to processes for the manufacture of certain intermediates useful in the manufacture of the quinazoline derivatives and to processes for the manufacture of the quinazoline derivatives utilising said intermediates. In particular, the present invention relates to chemical processes and intermediates useful in the manufacture of the compound 4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline.Type: ApplicationFiled: October 31, 2007Publication date: September 11, 2008Applicant: AstraZeneca ABInventors: Euan Alexander Arnott, John Crosby, Mathew Charles Evans, James Gair Ford, Martin Francis Jones, Kevin William Leslie, Ian Michael McFarlane, George Joseph Sependa
-
Patent number: 6255326Abstract: This invention is directed to the pharmaceutical use of phenyl compounds, which are linked to an aryl moiety by various linkages, for inhibiting tumor necrosis factor. The invention is also directed to the compounds, their preparation and pharmaceutical compositions containing these compounds. Furthermore, this invention is directed to the pharmaceutical use of the compounds for inhibiting cyclic AMP phosphodiesterase.Type: GrantFiled: January 27, 1999Date of Patent: July 3, 2001Assignee: Aventis Pharma LimitedInventors: Michael John Ashton, David Charles Cook, Garry Fenton, Susan Jacqueline Hills, Ian Michael McFarlane, Andrew David Morley, Malcolm Norman Palfreyman, Andrew James Ratcliffe, Brian William Sharp, Sukanthini Thurairatnam, Bernard Yvon Jack Vacher, Nigel Vicker
-
Patent number: 6096768Abstract: This invention is directed to the pharmaceutical use of phenyl compounds, which are linked to an aryl moiety by various linkages, for inhibiting tumor necrosis factor. The invention is also directed to the compounds, their preparation and pharmaceutical compositions containing these compounds. Furthermore, this invention is directed to the pharmaceutical use of the compounds for inhibiting cyclic AMP phosphodiesterase.Type: GrantFiled: April 29, 1999Date of Patent: August 1, 2000Assignee: Rhone-Poulenc Rorer LimitedInventors: Michael John Ashton, David Charles Cook, Garry Fenton, Susan Jacqueline Hills, Ian Michael McFarlane, Andrew David Morley, Malcolm Norman Palfreyman, Andrew James Ratcliffe, Brian William Sharp, Sukanthini Thurairatnam, Bernard Yvon Jack Vacher, Nigel Vicker
-
Patent number: 5935978Abstract: This invention is directed to the pharmaceutical use of phenyl compounds, which are linked to an aryl moiety by various linkages, for inhibiting tumor necrosis factor. The invention is also directed to the compounds, their preparation and pharmaceutical compositions containing these compounds. Furthermore, this invention is directed to the pharmaceutical use of the compounds for inhibiting cyclic AMP phosphodiesterase.Type: GrantFiled: July 28, 1993Date of Patent: August 10, 1999Assignee: Rhone-Poulenc Rorer LimitedInventors: Garry Fenton, Andrew David Morley, Malcolm Norman Palfreyman, Andrew James Ratcliffe, Brian William Sharp, Sukanthini Thurairatnam, Bernard Yvon Jack Vacher, Michael John Ashton, David Charles Cook, Susan Jacqueline Hills, Ian Michael McFarlane, Nigel Vicker